On Tuesday, Chinese 3D printing pharmaceutical company Triastek announced the completion of several hundred million yuan in a B+ round of financing. The investment is led by Triwise Capital, and previous shareholders Matrix Partners and Yunqi Partners followed the funding.
In June this year, Triastek completed 330 million yuan ($51.63 million) of B round financing. This round of financing will be mainly used for talent recruitment and business cooperation.
Founded in 2015, Triastek focuses on the field of 3D printing drugs. The company is committed to building a novel 3D printing pharmaceutical technology platform, covering the whole chain of drug dosage form design, digital development and intelligent production. At present, as the first Chinese pharmaceutical company to be accepted into the US FDA’s Emerging Technology Program, Triassic is participating in the formulation of the US Pharmacopoeia 3D printing drug industry standards.
After six years of development, Triassic has been at the forefront of the 3D printing drug industry. The patents held by the company account for more than 1/5 of the worldwide patent applications in the field of 3D printing drugs. Triassic will soon build an intelligent 3D printing drug production line with an annual capacity of 50 million tablets.
According to data of iiMedia Research, the global market for 3D printing, materials and services reached $12.76 billion in 2020, and is expected to surge to $49.1 billion in 2025.